Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)-Reference-Cited by-同舟云学术

Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)

Published:2018-01-29 Issue:7 Volume:53 Page:852-862
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Bader Peter,Kuçi Zyrafete,Bakhtiar Shahrzad,Basu Oliver,Bug Gesine,Dennis Michael,Greil Johann,Barta Aniko,Kállay Krisztián M.^ORCID,Lang Peter,Lucchini Giovanna,Pol Raj,Schulz Ansgar,Sykora Karl-Walter,von Luettichau Irene,Herter-Sprie Grit,Uddin Mohammad Ashab,Jenkin Phil,Alsultan Abdulrahman,Buechner Jochen,Stein Jerry,Kelemen Agnes,Jarisch Andrea,Soerensen Jan,Salzmann-Manrique Emilia,Hutter Martin,Schäfer Richard,Seifried Erhard,Klingebiel Thomas,Bonig Halvard,Kuçi Selim

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0102-z.pdf

Reference30 articles.

1. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63.

2. Deeg HJ. How I treat refractory acute GVHD. Blood. 2007;109:4119.

3. Hashmi S, Ahmed M, Murad MH, Litzow MR, Adams RH, Ball LM, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3:e45–e52.

4. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2062–8.

5. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439–41.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Approaches for the Prevention and Treatment of Acute and Chronic GVHD;Cells;2024-09-11

2. The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review;Frontiers in Cell and Developmental Biology;2024-07-26

3. Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience;Frontiers in Pediatrics;2024-05-09

4. International Society for Cell and Gene Therapy Clinical Translation Committee recommendations on mesenchymal stromal cells in graft-versus-host disease: easy manufacturing is faced with standardizing and commercialization challenges;Cytotherapy;2024-05

5. The Treatment of Steroid-Refractory Severe Gastrointestinal Acute Graft-Versus-Host Disease in Children after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre Experience;OSMANGAZİ JOURNAL OF MEDICINE;2024-04-04